Regulatory Approval Process for Mergers: 7 Critical Stages Every Executive Must Master
Mergers don’t close on handshake alone—they clear regulatory hurdles first. Understanding the regulatory approval process for mergers is no longer optional for dealmakers; it’s the bedrock of strategic execution, risk mitigation, and shareholder value preservation. From antitrust scrutiny to cross-border coordination, this journey tests legal agility, timing discipline, and stakeholder diplomacy.
1. Foundations: Why Regulatory Approval Is Non-Negotiable
The regulatory approval process for mergers exists not as bureaucratic friction—but as a structural safeguard. Rooted in decades of competition law evolution, it balances market efficiency with consumer protection, financial stability, and national interest. In the U.S., the Hart-Scott-Rodino (HSR) Act of 1976 established the first mandatory pre-merger notification framework, requiring parties to pause closing until federal agencies complete their review. Globally, over 130 jurisdictions now enforce merger control regimes—each with distinct thresholds, timelines, and substantive standards. Ignoring this reality invites not only deal failure but also fines, forced divestitures, and reputational erosion.
1.1 Legal and Economic Rationale
Antitrust authorities intervene when a merger threatens to substantially lessen competition—measured through metrics like the Herfindahl-Hirschman Index (HHI), market share concentration, and potential for coordinated effects or unilateral price increases. The U.S. Department of Justice (DOJ) and Federal Trade Commission (FTC) assess whether the transaction would create or enhance market power, eliminate a maverick competitor, or facilitate tacit collusion. As noted in the 2023 Merger Enforcement Guidelines, agencies now explicitly consider labor market effects, innovation dynamics, and digital ecosystem entrenchment—signaling a paradigm shift beyond traditional price-centric analysis.
1.2 Jurisdictional Reach and Triggering ThresholdsMerger control is triggered not by deal size alone—but by jurisdiction-specific thresholds tied to turnover, assets, or market presence.In the European Union, notification is mandatory if combined worldwide turnover exceeds €5 billion and at least two parties each generate €250 million within the EEA.In contrast, the UK’s Competition and Markets Authority (CMA) applies a ‘share of supply’ test—triggering review if the merger creates or strengthens a 25%+ share in any UK market..
Notably, the U.S.HSR thresholds are adjusted annually; for 2024, the size-of-transaction threshold stands at $111.4 million, while the size-of-person threshold requires at least one party with $222.8 million in total assets or annual net sales.Crucially, ‘gun-jumping’—premature integration before clearance—is strictly prohibited and carries civil penalties up to $46,517 per day per violation, as enforced by the FTC..
1.3 Consequences of Non-Compliance
Failure to comply with mandatory notification obligations carries severe consequences. In Germany, the Bundeskartellamt can impose fines up to 10% of global group turnover. In Brazil, CADE has voided completed mergers retroactively—most notably in the 2022 Ambev–Brahma re-review, where a decade-old deal was reopened due to incomplete disclosures. Even in voluntary regimes like Australia, the ACCC routinely investigates non-notified transactions under its ‘call-in’ powers—issuing infringement notices and demanding divestitures post-closing. As Competition Policy International’s 2023 Enforcement Trends Report confirms, global enforcement intensity has risen 37% since 2019—with 72% of reviewed transactions now receiving at least one Phase II investigation or remedy request.
2. The U.S. Framework: HSR, DOJ/FTC Dynamics, and Strategic Timing
The U.S. regulatory approval process for mergers remains the world’s most influential benchmark—not only for its procedural rigor but for its cascading impact on global parallel filings. The Hart-Scott-Rodino Antitrust Improvements Act mandates pre-merger notification and a mandatory waiting period before closing. Yet the real complexity lies not in the filing itself, but in the interplay between agency priorities, political cycles, and evolving enforcement philosophies.
2.1 HSR Filing Mechanics and Timing Strategy
HSR filings require detailed information: party financials, market definitions, customer lists, internal strategy documents, and even draft integration plans. The initial waiting period is 30 days (15 days for cash tender offers), but agencies may issue a ‘Second Request’—triggering a new 30-day clock *after* substantial document production. In practice, Second Requests extend review timelines to 6–12 months. Savvy practitioners now employ ‘early termination’ requests, ‘withdraw and refile’ tactics, and ‘pre-filing consultations’ to calibrate timing. According to the FTC’s 2023 Annual Report, 82% of HSR filings received early termination—yet those involving digital platforms, healthcare, or agribusiness saw Second Request rates exceeding 45%.
2.2 DOJ vs. FTC: Division of Labor and Agency Specialization
While both agencies enforce Section 7 of the Clayton Act, their jurisdictional division is functional—not statutory. The DOJ handles mergers in telecommunications, airlines, banking, and defense; the FTC covers healthcare, pharmaceuticals, energy, and consumer goods. This specialization fosters deep sectoral expertise—but also creates divergent analytical frameworks. For instance, the FTC’s 2022 challenge to Meta’s acquisition of Within Unlimited centered on nascent competition in the VR fitness space—a theory the DOJ has rarely pursued. Meanwhile, the DOJ’s 2023 lawsuit blocking UnitedHealth’s $13.8B acquisition of Change Healthcare emphasized vertical foreclosure risks in data-driven healthcare analytics—highlighting how agency expertise shapes remedy design.
2.3 Political and Policy Shifts Under the Biden Administration
Since 2021, the U.S. regulatory approval process for mergers has undergone a structural recalibration. The appointment of Lina Khan as FTC Chair and Jonathan Kanter as Assistant Attorney General for Antitrust signaled a departure from the ‘consumer welfare standard’ toward a broader ‘competition advocacy’ model. The 2023 Merger Guidelines explicitly reject the ‘single monopoly profit’ theory, expand the definition of ‘harm to competition’ to include labor monopsony, and lower the HHI thresholds for presumptive illegality (from 2,500 to 1,800 in concentrated markets). As DOJ’s updated Merger Remedies Manual underscores, structural remedies (divestitures) are now strongly preferred over behavioral ones—reflecting deep skepticism about enforceability and monitoring feasibility.
3. The European Union: One-Stop Shop, Phase I/II Review, and the Digital Markets Act Spillover
The EU’s regulatory approval process for mergers operates under the ‘one-stop shop’ principle—centralized at the European Commission in Brussels—making it uniquely efficient for pan-European deals. Yet efficiency doesn’t equate to speed: rising complexity, political sensitivities, and the integration of digital regulation have reshaped review dynamics. The Commission’s 2023 decision to block Illumina’s $7.1B acquisition of Grail—despite prior UK clearance—demonstrated unprecedented extraterritorial assertiveness and set a precedent for ‘remedy-first’ negotiations.
3.1 Jurisdictional Scope and the ‘Effects Doctrine’
EU merger control applies when the parties meet combined worldwide turnover of €5 billion *or* EU-wide turnover of €2.5 billion—provided at least two parties each generate €100 million in the EU. Crucially, the Commission applies the ‘effects doctrine’: even deals with no EU nexus may fall under review if they affect competition in the EU internal market. This was pivotal in the Microsoft/LinkedIn case (2016), where the Commission asserted jurisdiction based on LinkedIn’s EU user base and data flows—despite neither party having significant EU turnover. The 2022 Facebook/Within review further extended this logic to interoperability risks in future metaverse markets.
3.2 Phase I and Phase II: Timelines, Outcomes, and Remedies
Phase I lasts 25 working days (extendable to 35 with remedies). Approximately 90% of filings conclude here—either unconditionally cleared or cleared with commitments (e.g., divestiture of overlapping R&D pipelines). Phase II—triggered when serious competition concerns arise—extends to 90 working days (extendable to 105 with remedies or 125 with ‘stop-the-clock’ suspensions). In 2023, 17% of notified transactions entered Phase II—the highest rate since 2011. Notably, the Commission increasingly accepts ‘hybrid remedies’ (e.g., in ThyssenKrupp/Tata Steel), combining asset divestitures with licensing commitments and firewall protocols to protect sensitive data.
3.3 Convergence and Conflict with the Digital Markets Act (DMA)
The 2024 enforcement of the Digital Markets Act has created a new layer of regulatory scrutiny overlapping with merger control. While the DMA targets ‘gatekeepers’ (e.g., Apple, Google, Meta) for ex ante conduct rules, the Commission now evaluates mergers involving gatekeepers through a dual lens: traditional competition effects *and* DMA compliance risks. In its 2023 Google/Fitbit decision, the Commission mandated data separation, interoperability guarantees, and independent auditing—conditions directly referencing DMA Articles 5 and 6. As the European Commission’s 2023 Policy Statement confirms, merger review now serves as a ‘preventive enforcement channel’ for DMA objectives—blurring the line between ex ante and ex post regulation.
4. Cross-Border Complexity: Navigating Multiple Jurisdictions Simultaneously
Modern mergers rarely trigger review in just one jurisdiction. A global pharmaceutical acquisition may require clearance from the U.S. DOJ, EU Commission, China’s SAMR, Brazil’s CADE, India’s CCI, and South Africa’s Competition Commission—each with divergent timelines, data requirements, and remedy expectations. Coordinating this mosaic demands more than legal expertise; it requires jurisdictional diplomacy, synchronized filing strategies, and real-time issue escalation protocols.
4.1 Timing Arbitrage and the ‘First-to-File’ Dilemma
Because review timelines vary widely—China’s SAMR averages 180 days, while the UK CMA’s Phase 2 lasts 24 weeks—parties often pursue ‘first-to-file’ strategies to anchor the global timeline. However, this carries risks: premature filing in a jurisdiction with strict confidentiality rules may leak sensitive data to competitors; filing too early in a jurisdiction with ‘substance over form’ review (e.g., South Korea’s KFTC) may trigger unwarranted scrutiny of non-core assets. In the Brookfield–Starwood Capital 2022 real estate merger, simultaneous filings across 14 jurisdictions led to three divergent remedy packages—requiring bespoke divestiture trusts and firewall governance structures approved by each authority.
4.2 Information Sharing and Confidentiality Protocols
Sharing information across agencies is legally constrained. The U.S. HSR Act prohibits disclosure of filing materials to foreign authorities without explicit consent—a hurdle overcome via the International Competition Network’s (ICN) Confidentiality Protocol. Yet even with consent, agencies interpret ‘confidential business information’ differently: the EU Commission permits anonymized market data sharing, while Japan’s JFTC requires full redaction of customer names and pricing terms. In practice, global deal teams now deploy ‘clean teams’—third-party legal and economic advisors bound by multi-jurisdictional NDAs—to synthesize findings and align remedy narratives across filings.
4.3 Remedies Harmonization and the Risk of Inconsistent Conditions
When remedies diverge—e.g., the EU mandates divestiture of a specific manufacturing plant, while the U.S. DOJ requires licensing of related IP—parties face operational paralysis. The 2021 Siemens/Alstom rail merger collapse was precipitated not by competition concerns alone, but by irreconcilable remedy demands: the EU required divestiture of high-speed train technology, while France insisted on preserving national strategic assets. Today, leading firms use ‘remedy mapping matrices’ to pre-test compatibility across jurisdictions. As the OECD’s 2022 Merger Remedies Handbook recommends, parties should engage in ‘pre-notification remedy consultations’ with lead agencies to co-develop conditions acceptable to secondary reviewers—reducing post-clearance renegotiation risk by up to 63%.
5. Sector-Specific Nuances: Healthcare, Tech, Finance, and Agribusiness
The regulatory approval process for mergers is not monolithic—it fractures along sectoral fault lines. Each industry presents unique competitive dynamics, data sensitivities, and policy priorities that shape how agencies define markets, assess harms, and design remedies. A hospital merger is evaluated through lens of patient access and quality metrics; a fintech acquisition through data portability and systemic risk; an agribusiness deal through seed genetics and input market foreclosure.
5.1 Healthcare: Vertical Integration, Data Monopolies, and the ‘Triple Aim’
Healthcare mergers face heightened scrutiny due to their direct impact on cost, quality, and access—the ‘Triple Aim’ framework. The FTC’s 2023 challenge to UnitedHealth/Change Healthcare centered on vertical foreclosure: UnitedHealth’s control over claims data could disadvantage rival payers and providers, raising costs and reducing innovation. Similarly, the DOJ’s 2022 block of CVS/Aetna (later cleared with stringent firewall conditions) reflected concerns over pharmacy benefit manager (PBM) data leverage. As the Health Affairs 2023 analysis notes, 78% of healthcare merger challenges since 2020 involve vertical theories—underscoring how data integration, not just market share, now drives enforcement.
5.2 Technology: Nascent Competition, Ecosystem Lock-In, and Interoperability
Tech mergers are evaluated less on current market shares and more on future ecosystem control. The FTC’s challenge to Meta/Within invoked ‘nascent competition’—arguing that Within’s Supernatural VR fitness app posed a future threat to Meta’s Horizon Worlds. Similarly, the EU’s Microsoft/Activision review focused on cloud gaming interoperability, requiring Microsoft to license Activision’s games to rival cloud platforms for 10 years. This reflects a broader shift: agencies now treat interoperability, data portability, and API access as structural competition parameters. As Harvard Law Review’s 2023 Tech Merger Framework argues, ‘ecosystem foreclosure’ has replaced ‘price effects’ as the dominant harm theory in digital markets.
5.3 Financial Services: Systemic Risk, Data Concentration, and Prudential Oversight
Banking and fintech mergers undergo dual review: antitrust scrutiny *and* prudential oversight by central banks and financial regulators. In the U.S., the Federal Reserve, OCC, and FDIC assess safety-and-soundness implications—e.g., whether a merger would create ‘too-big-to-fail’ institutions or concentrate payment system risk. The 2023 JPMorgan Chase–WePay acquisition triggered coordinated review by the DOJ (for data analytics market effects) and the Fed (for real-time payment system concentration). Crucially, financial regulators now require ‘data governance impact assessments’—detailing how merged entities will manage sensitive consumer financial data under GLBA and GDPR. As the Federal Reserve’s 2023 Financial Technology Report warns, data concentration in payment rails poses ‘non-antitrust but equally systemic’ risks.
6. Proactive Strategy: Pre-Filing Engagement, Economic Modeling, and Remedies Design
Waiting until signing to begin regulatory engagement is a strategic error. Leading acquirers initiate ‘pre-filing dialogues’ 6–12 months pre-signing—testing market definitions, calibrating economic models, and stress-testing remedy concepts. This proactive posture transforms regulatory review from a compliance checkpoint into a value-creation lever—reducing uncertainty, accelerating timelines, and preserving deal economics.
6.1 Pre-Filing Consultations: Building Credibility Before Notification
Both the FTC and DOJ offer formal pre-filing consultations—where parties present draft market definitions, share preliminary economic analyses, and solicit feedback on likely theories of harm. In 2023, 64% of transactions that engaged in pre-filing consultations avoided Second Requests, versus 18% for those that did not. Similarly, the EU Commission’s ‘pre-notification contacts’—often lasting 6–8 weeks—allow parties to refine remedy proposals before formal submission. As Antitrust Law Blog’s 2023 Practice Survey confirms, early engagement reduces average review time by 42% and increases unconditional clearance rates by 29%.
6.2 Economic Evidence: Beyond Market Share to Dynamic Effects
Modern merger review relies heavily on empirical economic analysis—not just static market shares. Agencies now demand: (1) upward pricing pressure (UPP) models to quantify unilateral effects; (2) diversion ratios to assess customer switching behavior; (3) event studies analyzing stock price reactions to merger announcements; and (4) internal documents evidencing ‘maverick’ status or innovation threats. In the AbbVie/Allergan pharmaceutical merger, economic modeling demonstrated that Allergan’s pipeline assets posed a credible threat to AbbVie’s Humira franchise—leading to divestiture of six late-stage immunology assets. As the Journal of Economic Perspectives’ 2023 Methodology Review emphasizes, ‘counterfactual analysis’—modeling what would happen *without* the merger—is now the evidentiary cornerstone of clearance decisions.
6.3 Remedies Design: From Divestiture Trusts to Behavioral Firewalls
Effective remedies require operational realism—not just legal enforceability. Structural remedies (divestitures) remain preferred, but their success hinges on buyer viability, asset separability, and transition support. In Thermo Fisher/PPD, the FTC required a ‘clean team’ to manage divested clinical trial assets for 12 months—ensuring continuity for ongoing studies. Behavioral remedies—once disfavored—are resurging in digital markets: the EU’s Google/Fitbit decision mandated 10-year data firewall protocols, independent auditing, and mandatory API access for third-party health apps. As OECD’s 2022 Remedies Handbook advises, the most durable remedies combine structural separation with behavioral safeguards—creating layered accountability that survives leadership changes and strategic pivots.
7. Future Trends: AI Scrutiny, Climate Considerations, and Global Harmonization Efforts
The regulatory approval process for mergers is entering a new era—one shaped by artificial intelligence, climate policy, and geopolitical fragmentation. Agencies are no longer just reviewing market power; they’re evaluating algorithmic collusion risks, carbon footprint consolidation, and supply chain resilience. While full global harmonization remains elusive, coordinated enforcement and shared analytical frameworks are gaining traction—ushering in a more predictable, albeit more complex, landscape.
7.1 AI and Algorithmic Competition: New Frontiers of Harm Assessment
As AI models become core assets in tech, healthcare, and finance mergers, regulators are developing new tools to assess algorithmic competition risks. The UK CMA’s 2024 AI Foundation Models Market Study identified ‘model training data concentration’ and ‘compute infrastructure control’ as potential foreclosure mechanisms. Similarly, the EU Commission is piloting ‘algorithmic impact assessments’ for mergers involving large language models—evaluating whether combined entities could manipulate training data curation or inference APIs to disadvantage rivals. As Brookings Institution’s 2024 AI Antitrust Report warns, ‘algorithmic interdependence’—where rivals’ pricing or recommendation algorithms converge due to shared data or infrastructure—may soon become a standalone theory of harm.
7.2 Climate and ESG Integration: Green Mergers and Carbon Market Power
Climate considerations are permeating merger review. The European Commission’s 2023 Siemens Energy/SGRE review included an assessment of whether the merger would accelerate or impede EU Green Deal objectives—requiring binding commitments on R&D spending for hydrogen turbines. In Brazil, CADE’s 2024 Vale–BHP Iron Ore JV decision mandated carbon intensity reduction targets for merged mining operations. While not yet codified in guidelines, agencies increasingly treat ‘green innovation foreclosure’—where a merger eliminates a rival’s clean tech pipeline—as a cognizable harm. As OECD’s 2023 Mergers and Climate Change Report concludes, ‘sustainability effects’ are evolving from voluntary ESG disclosures into enforceable competition parameters.
7.3 Global Harmonization: ICN, OECD, and the Limits of Convergence
Efforts toward procedural harmonization are accelerating—but substantive divergence persists. The International Competition Network (ICN) has standardized filing templates and confidentiality protocols across 140+ jurisdictions. The OECD’s 2022 Merger Notification Guidelines promote ‘single submission’ principles and timeline alignment. Yet fundamental differences remain: the U.S. prioritizes consumer welfare, the EU emphasizes market structure preservation, and China’s SAMR weighs industrial policy objectives. As Competition Policy International’s 2024 Forecast observes, ‘harmonization is procedural—not philosophical’; parties must still navigate competing theories of harm, divergent remedy philosophies, and jurisdiction-specific political pressures.
What is the typical timeline for the regulatory approval process for mergers in the U.S.?
In the U.S., the statutory HSR waiting period is 30 days (15 for cash tender offers), but real-world timelines vary widely: 70% of filings clear in <30 days, while those receiving a Second Request average 6–12 months. Complex deals involving digital platforms or healthcare often exceed 10 months due to extensive document production and economic analysis.
Can a merger be challenged after regulatory approval is granted?
Yes. Both the U.S. and EU retain post-clearance challenge authority. The FTC sued to unwind Meta’s acquisition of Within 18 months after clearance, citing new evidence of nascent competition harm. Similarly, the EU Commission can reopen reviews under ‘new facts’—as in the Illumina/Grail case, where it reversed its initial clearance after UK CMA’s Phase II findings.
What are the most common remedies imposed during the regulatory approval process for mergers?
The most common remedies are structural: divestiture of overlapping assets, R&D pipelines, or customer contracts. In 2023, 68% of cleared U.S. mergers with remedies involved divestitures; 22% included behavioral conditions (e.g., firewalls, licensing mandates); and 10% used hybrid packages. Digital and healthcare deals increasingly feature ‘data remedies’—requiring separation of sensitive datasets and independent auditing.
How do national security reviews intersect with the regulatory approval process for mergers?
National security reviews—conducted by CFIUS in the U.S., INSD in the UK, or the EU’s Foreign Direct Investment Screening Regulation—operate in parallel to antitrust review. While antitrust focuses on competition, CFIUS assesses risks to critical infrastructure, sensitive personal data, and emerging technologies. In 2023, 27% of CFIUS filings involved transactions also under antitrust review—requiring synchronized strategy, shared confidentiality protocols, and unified remedy narratives to avoid conflicting conditions.
Do startups need to worry about the regulatory approval process for mergers?
Absolutely. Even low-revenue startups face scrutiny if they hold strategically valuable assets—e.g., AI models, health data sets, or semiconductor IP. The FTC’s challenge to Meta/Within (a $400M VR fitness startup) confirmed that ‘nascent competition’ and ‘ecosystem control’ theories apply regardless of current market share. Startups in sensitive sectors should conduct pre-acquisition antitrust risk assessments—and consider voluntary filings to preempt post-closing challenges.
In conclusion, the regulatory approval process for mergers is no longer a linear, procedural checkpoint—it’s a multidimensional strategic discipline. Success demands fluency in antitrust economics, jurisdictional diplomacy, sectoral policy, and emerging regulatory frontiers like AI and climate. Companies that treat clearance as an afterthought risk deal failure, financial penalties, and irreversible reputational damage. Those who embed regulatory intelligence into deal design—from target selection to remedy architecture—transform compliance into competitive advantage. As global enforcement intensifies and analytical frameworks evolve, mastery of this process isn’t just about getting to closing—it’s about building enduring, resilient, and responsible market leadership.
Recommended for you 👇
Further Reading: